As oxygen is essential for many metabolic pathways, tumour hypoxia may impair cancer cell proliferation 1-4 . However, the limiting metabolites for proliferation under hypoxia and in tumours are unknown. Here, we assessed proliferation of a collection of cancer cells following inhibition of the mitochondrial electron transport chain (ETC), a major metabolic pathway requiring molecular oxygen 5 . Sensitivity to ETC inhibition varied across cell lines, and subsequent metabolomic analysis uncovered aspartate availability as a major determinant of sensitivity. Cell lines least sensitive to ETC inhibition maintain aspartate levels by importing it through an aspartate/ glutamate transporter, SLC1A3. Genetic or pharmacologic modulation of SLC1A3 activity markedly altered cancer cell sensitivity to ETC inhibitors. Interestingly, aspartate levels also decrease under low oxygen, and increasing aspartate import by SLC1A3 provides a competitive advantage to cancer cells at low oxygen levels and in tumour xenografts. Finally, aspartate levels in primary human tumours negatively correlate with the expression of hypoxia markers, suggesting that tumour hypoxia is sufficient to inhibit ETC and, consequently, aspartate synthesis in vivo. Therefore, aspartate may be a limiting metabolite for tumour growth, and aspartate availability could be targeted for cancer therapy.
blood, stomach, breast, colon and lung tumours, and measured the effect of ETC inhibition on cell proliferation (Fig. 1a ). Given that inhibition of different complexes of the ETC may have pleiotropic effects on metabolism, we used inhibitors of complex I (piericidin), complex III (antimycin A) and complex V (oligomycin) as well as phenformin, an anti-diabetic drug that inhibits the ETC. Interestingly, cancer cell lines display diverse growth responses to ETC inhibition ( Fig. 1a ). While proliferation of many lines was strongly affected by ETC inhibitors, a subset was less sensitive or some were completely resistant to ETC inhibition. The sensitivity to inhibition of each ETC complex significantly correlated with the others, suggesting that the effect of ETC inhibition on proliferation is largely independent of the complex inhibited ( Fig. 1a and Supplementary Fig. 1a ). However, a subset of cancer cell lines exhibited sensitivity to ETC inhibition that was partially complex dependent. For example, the sensitivity profiles of complexes I and III inhibition were more highly correlated with each other than with that of complex V inhibition, reflecting the distinct functions of complexes I/III and V in the ETC. Similarly, the sensitivity profile of complex I inhibitor piericidin most strongly correlated with that of phenformin (r = 0.90, P = 1.7 × 10 −11 ) ( Fig. 1b and Supplementary  Fig. 1a ), consistent with the previous findings that the major cellular target of anti-diabetic biguanides such as metformin and phenformin is complex I 14, 15 .
Given these results, we hypothesized that fundamental differences in metabolic function might exist between the cancer cell lines most sensitive (P12-ICHIKAWA, ALL-SIL, HPB-ALL, MV-4-11, A549 and SU-DHL-8) and least sensitive (COLO-704, MDA-MB-157, NOMO-1, RPMI-8226, COLO-320DM and SNU-1) to ETC inhibition . To understand why a subset of cancer cell lines is less sensitive to ETC inhibition, we compared the effects of piericidin treatment on levels of key metabolites in the two groups ( Fig. 1c ). Even though ETC inhibition caused profound changes in the metabolism of all cancer cell lines, we were only able to detect significant differences in 19 metabolites between the two groups ( Fig. 1c and Supplementary Fig. 1b ). Among these were TCA cycle intermediates (malate, citrate and fumarate), nucleotides (UMP, ADP, UDP and CDP) and the amino acids aspartate and argininosuccinate. Synthesis of aspartate is limiting for cancer cell proliferation when ETC is impaired 16, 17 , and aspartate is a precursor for the synthesis of many of these metabolites including argininosuccinate and nucleotides. We therefore focused our attention on aspartate and asked whether the change in aspartate levels might determine the response to ETC inhibition. Indeed, among all amino acids, Letters NATurE CELL BIoLoGy aspartate is the only one that drops substantially (~3-fold) in ETCinhibition-sensitive cancer cell lines, while its levels are mostly maintained in the resistant counterparts ( Fig. 1d ). Therefore, our results strongly point to the change in aspartate levels as an important determinant of sensitivity to ETC inhibition across different cancer cell lines.
We next sought to understand how a subset of cancer cells could maintain aspartate levels under ETC inhibition and whether maintenance of aspartate levels decreases sensitivity to ETC inhibition. Cells can increase aspartate availability by (1) increasing de novo synthesis from oxaloacetate or (2) importing aspartate from the extracellular environment. Remarkably, unlike ETC-inhibition-sensitive cells, the majority of ETC-inhibition-resistant cell lines (COLO-704, MDA-MB-157, NOMO-1, COLO 320DM and SNU-1) were naturally able to uptake extracellular 14 C-labelled aspartate ( Fig. 2a and Supplementary Fig. 2a ), indicating that increased aspartate transport may account for the observed resistance to ETC inhibition. Indeed, standard RPMI media lacking aspartate, but not the structurally similar glutamate, sensitizes otherwise resistant cancer cells displaying aspartate import to ETC inhibitors ( Fig. 2b and Supplementary Fig.  2b ). These results suggest that maintaining aspartate levels by import enables cancer cell proliferation under ETC inhibition.
Aspartate is a charged amino acid at physiological pH and requires the presence of specific transporters for cellular import ( Supplementary Fig. 2c ), as most mammalian cells cannot uptake aspartate from their environment 18 . Expression of these known transporters is normally restricted to neuronal tissues 18 . To identify the transporter(s) that import aspartate in ETC inhibition resistant cancer cell lines, we asked whether the expression of any particular transporter is most predictive of the response to ETC inhibition. Correlation of antimycin's effect on cell viability with transcriptome-wide mRNA expression data from the Cancer Cell Line Encyclopedia (CCLE) 19 revealed the aspartate/glutamate transporter SLC1A3 as a top scoring gene (r = 0.64, P = 2.9 × 10 −4 ) ( Fig. 2c ). Indeed, many of the cancer cell lines with detectable aspartate import activity express SLC1A3 protein ( Fig. 2d ). One exception to this correlation, COLO-704, expresses SLC1A2, a close homologue of SLC1A3, which is also capable of importing aspartate ( Supplementary Fig. 2d ,e). Two additional resistant cell lines (RPMI 8226 and DU4475) do not import aspartate, suggesting the existence of alternative mechanisms to overcome ETC inhibition.
SLC1A3 is a glutamate-aspartate transporter localized on the plasma membrane ( Supplementary Fig. 2f ) and normally expressed Table 1 . Statistics source data are provided in Supplementary Table 1 .
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in glial cells 20 . However, SLC1A3 is also highly expressed in a subset of non-glial epithelial tumours and its genomic locus is significantly amplified ( Supplementary Fig. 2g ). To determine whether SLC1A3 expression is necessary for cancer cell proliferation under ETC inhibition, we used the CRISPR/Cas9 system and generated a clonal SLC1A3 knockout of the SNU-1 cell line (SLC1A3_KO), in which SLC1A3 is normally highly expressed ( Fig. 2e ). SLC1A3_KO cells take up 10-fold less aspartate and are more sensitive to piericidin and antimycin than wild-type counterparts ( Fig. 2f,g) . Importantly, expression of an sgSLC1A3-resistant human SLC1A3 cDNA in the 14 C-Aspartate uptake in ETC-inhibition-resistant and -sensitive cancer cell lines (mean ± S.E.M., n = 3 biologically independent samples). b, Aspartate depletion sensitizes aspartate-importing cancer cell lines to ETC inhibitors. L-aspartate (150 μ M), antimycin (AntiA, 30 nM) and piericidin (Pier., 10 nM) were added as indicated (mean ± S.E.M., 5 cell lines in each group, n = 3 biologically independent samples). c, Correlation of the sensitivities to ETC inhibitors with transcriptome-wide mRNA expression data from the Cancer Cell Line Encyclopedia (CCLE). The resulting Pearson correlation coefficients were sorted and plotted. SLC1A3 is indicated. n = 28 cell lines from Fig. 1a . d, Immunoblot analysis of SLC1A3 in ETC-inhibition-resistant and -sensitive cell lines. Actin was used as a loading control. e, Immunoblot analysis of SLC1A3 in wild-type, SLC1A3-null and rescued null SNU-1 cells. Actin was used as a loading control. f, 14 C-aspartate uptake in wild-type, SLC1A3-null and SNU-1 cells treated with an SLC1A3 inhibitor (TFB-TBOA, 20 μ M) (mean ± S.E.M., n = 3 biologically independent samples). g, Loss of SLC1A3 sensitizes cancer cells to antimycin and piericidin in RPMI. Relative cell number of wild-type (black), SLC1A3-null (blue) and rescued SLC1A3null (grey) SNU-1 cells in the absence and presence of pyruvate (1 mM) or TFB-TBOA (20 μ M) after treatment with piericidin (10 nM) and antimycin (30 nM) for 5 days (mean ± S.E.M., n = 3 biologically independent samples). h, Pharmacologic inhibition of SLC1A3 sensitizes aspartate importing cancer cell lines to antimycin (30 nM) and piericidin (10 nM). Cells were grown for 5 days in the absence or presence of TFB-TBOA (20 μ M) (mean ± S.D., 5 cell lines in each group, n = 3 biologically independent samples). i, Expression of SLC1A3 rescues A549 from the anti-proliferative effects of antimycin and piericidin in standard RPMI media, which contains 150 μ M aspartate. Relative cell number of control (black), and SLC1A3-overexpressing (grey) A549 cells in the absence and presence of pyruvate (1 mM) or TFB-TBOA (20 μ M) after treatment with piericidin (10 nM) and antimycin (30 nM) for 5 days. (mean ± S.E.M, n = 3 biologically independent samples). Statistics: two-tailed unpaired t-test. **P < 0.05, ***P < 0.01, ****P < 0.001. For individual P values, see Supplementary Table 1 . Statistics source data are provided in Supplementary Table. 1.
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null cells or addition of pyruvate, which facilitates aspartate synthesis despite ETC inhibition 21 , completely restored resistance to ETC inhibitors ( Fig. 2g ). Small molecule inhibitors targeting SLC1A3 (TFB-TBOA and UCPH-101) effectively block aspartate/glutamate uptake ( Fig. 2f) [22] [23] [24] . These pharmacologic inhibitors of SLC1A3 sensitize SNU-1 cells and other ETC-inhibition-resistant cell lines with high SLC1A3 expression, including those with SLC1A3 amplification (NCI-H596, SNU-182 and Detroit-562), to ETC inhibitors ( Fig. 2h and Supplementary Fig. 2h ,i). Additionally, we found that overexpression of SLC1A3 in A549, a cell line with undetectable endogenous SLC1A3 expression, is sufficient to enable the aspartate uptake and the proliferation of these cells under ETC inhibition ( Fig. 2i and Supplementary Fig. 2j ). Taken together, these findings reveal that SLC1A3 expression permits cancer cell proliferation under ETC inhibition, and that expression of the aspartate transporter SLC1A3 is a predictor of the proliferative response to ETC inhibition.
Aspartate levels can be limiting for cell proliferation under pharmacologic inhibition of mitochondrial respiration 16, 17 , but whether aspartate is a limiting metabolite under conditions relevant to tumour growth is not known. As cancer cells in tumours are often starved for oxygen due to dysfunctional vasculature, we hypothesized that insufficiency of oxygen probably restricts aspartate biosynthesis via impairing ETC function and redox balance ( Supplementary Fig. 3a ). To first test whether aspartate is depleted in hypoxia, we measured amino acid levels of A549 and PANC-1 cancer cells, which have no detectable SLC1A3 expression, in standard atmospheric oxygen conditions (21%) or in reduced oxygen similar to that found in hypovascularized tumours (0.5%) 25, 26 . Hypoxia causes profound metabolic changes, particularly a 4-fold decrease in the levels of aspartate and asparagine, which is synthesized from aspartate ( Fig. 3a and Supplementary Fig. 3b ). These data raise the possibility that low aspartate levels can limit proliferation under low oxygen, similar to what we observed for ETC inhibition, and that increasing aspartate levels may also promote proliferation in hypoxia. To test this possibility, we expressed SLC1A3 in A549 and PANC-1 cell lines as well as counterparts derived from Kras G12D /p53 −/− -driven lung and pancreas cancer mouse models (KP lung and KP pancreas). Expression of SLC1A3 in these four cancer cell lines raised aspartate levels and increased their proliferation rates in hypoxia ( Fig. 3b ,c). Improved proliferative capacity under hypoxia depends on the aspartate transport activity of SLC1A3, as aspartate depletion or inhibition of SLC1A3 with a small molecule inhibitor completely eliminates the rescue Results are plotted relative to cells cultured under 0.5% oxygen without aspartate or nucleoside supplementation. (mean ± S.E.M., n = 3 biologically independent samples, *P < 0.01, **P < 0.001, ***P < 0.0001). Statistics: two-tailed unpaired t-test. For individual exact P values, see Supplementary Table 1 . Statistics source data are provided in Supplementary Table 1 . phenotype (Fig. 3c ). While aspartate is present in standard RPMI media at a concentration of 150 μ M, its concentration in human and mouse serum is much lower (10-30 μ M) ( Supplementary Fig.  3c ) 27 . However, culturing SLC1A3-expressing cancer cells in physiological aspartate concentrations 27 is still sufficient to enable proliferation under ETC inhibition or hypoxia ( Supplementary Fig.  3e ,f), validating that SLC1A3 is a high-affinity transporter and can import aspartate at 20 μ M, a concentration on par with the levels of aspartate found in circulation. Therefore, our data indicate that aspartate is a major limiting metabolite for optimal cell proliferation under hypoxia.
We next asked whether low aspartate is also a metabolic limitation for tumour growth in vivo. To test the role of aspartate availability in tumour growth, we performed a competitive proliferation assay between vector and SLC1A3-infected A549 and KP lung cancer cells under hypoxia, pharmacologic ETC inhibition and as tumour xenografts. Indeed, exogenous expression of SLC1A3 provides a growth advantage compared to vector infected controls in hypoxia or upon ETC inhibition in culture, and in tumour xenografts ( Fig. 3d and Supplementary Fig. 3d ). Of note, SLC1A3-expressing tumours have 2-fold higher aspartate levels compared to wild-type counterparts ( Supplementary  Fig. 3g ). Aspartate limitation is not necessarily common to all cancers, as the growth advantage conferred by SLC1A3 expression was not observed in Kras mutant mouse pancreas tumours ( Supplementary Fig. 3h ). This suggests that some cancer types might meet their aspartate supply through alternative routes such as macropinocytosis in vivo [28] [29] [30] . Collectively, our results provide evidence that aspartate can be a growth-limiting metabolite in tumours.
Aspartate is a proteinogenic amino acid but can also contribute to nucleotide synthesis and TCA cycle anaplerosis. To understand why aspartate is limiting for cancer cell proliferation under hypoxia, we measured the generation of key metabolites derived from isotope labelled aspartate in A549 and PANC-1 cells. Aspartate can be directly used as a substrate to replenish the TCA cycle via the action of aspartate transaminases, generating citrate with four 13C atoms (m + 4) and malate with two 13C atoms (m + 2). However, we observe only modest labelling of malate/fumarate (m + 2) and citrate (m + 4) from 13 C-aspartate in these cell lines ( Supplementary Fig. 4a ). Consistent with this observation, SLC1A3 expression does not increase oxygen consumption, which would be expected if aspartate supplementation substantially drove TCA flux ( Supplementary Fig. 4b ). We then Letters NATurE CELL BIoLoGy focused our attention on the contribution of imported aspartate to nucleotide synthesis. In purine biosynthesis, aspartate acts as a nitrogen donor for both the purine ring and for the production of adenine from hypoxanthine. In pyrimidine biosynthesis, aspartate contributes three carbon atoms during the production of UMP and TMP via the intermediate orotate. Interestingly, 50 to 80% of orotate, dTMP and UMP in SLC1A3-expressing cells are derived from imported aspartate specifically under hypoxia and ETC inhibition, and only minimally under normoxic conditions ( Fig. 3e and Supplementary Fig. 4a ). Additionally, a significant portion of aspartate can contribute to purine synthesis as measured by [ 15 N]-aspartate incorporation into AMP in SLC1A3expressing cells ( Fig. 3e and Supplementary Fig. 3c ). We observed similar results even under physiological aspartate concentrations ( Supplementary Fig. 4d ). These observations raise the possibility that low aspartate levels might limit nucleotide production Remarkably, in 3 out of the 4 cell lines, nucleoside supplementation alone substantially rescued growth inhibition by hypoxia even in the absence of aspartate, consistent with the limiting role of nucleotide biosynthesis (Fig. 3f ). Thus, our data argue that imported aspartate is a major source for nucleotide biosynthesis and that aspartate-derived nucleotide synthesis is limiting for proliferation of a subset of cancer cells under hypoxia. Given our results demonstrating that hypoxic cells are deficient in aspartate production, we asked whether aspartate could be a metabolic marker predicting the degree of hypoxia in primary human tumours. Hypoxia activates a specific transcriptional program through hypoxia-inducible factors 31 , which strongly induces transcription of genes related to metabolism and angiogenesis, most notably VEGFA, CA9 and HK2 32 . To test whether tumour hypoxia impacts aspartate levels in glioblastomas, we collected 24 snap-frozen glioblastomas for metabolomics and transcriptomic analyses, and correlated mRNA expression of hypoxic markers with the abundance of individual metabolites. Remarkably, among 128 metabolites detected, steady-state aspartate levels correlate significantly (P < 0.01) with these established markers of tumour hypoxia ( Fig. 4a and Supplementary Fig. 4e,f) . Interestingly, steady-state aspartate levels correlated with the hypoxic markers even more strongly than lactate and acylcarnitines, metabolites commonly viewed as being increased in hypoxic tumour regions ( Fig. 4b) 33, 34 . These results suggest that the degree of hypoxia experienced by human tumours may inhibit aspartate synthesis through ETC inhibition, making aspartate a potential metabolite marker for tumour hypoxia in glioblastomas.
Our data are consistent with a model whereby tumour hypoxia limits ETC function, blocking aspartate availability and nucleotide biosynthesis ( Fig. 4c ). Similar to our results, heterologous expression of a guinea pig asparaginase also increases aspartate availability and tumour growth 35 . Consistent with this observation, the degree of ETC inhibition present in primary human tumours is sufficient to limit aspartate production, as hypoxic markers correlate with aspartate levels. While low aspartate levels may restrict tumour growth by impacting protein and nucleotide synthesis, nucleoside supplementation alone can restore proliferation of a subset of aspartate-limited cancer cells, implying differential metabolic needs of different cancer types under hypoxia. Finally, acquisition of the ability to import aspartate through upregulation of gene expression or genomic amplification of aspartate transporters may be an important metabolic adaptation for tumours that develop in or are selected by transient rounds of hypoxia. Our findings indicate that low oxygen levels may constrain in vivo tumour growth through aspartate limitation, and pathways relevant to aspartate availability could thus be targeted for therapy in a subset of tumours.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0118-z. 
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Methods Cell lines, compounds and constructs. Antibodies to SLC1A3 (GTX20262, 1:1,000 for western blot; 1:500 for immunofluorescence) and β -actin (GTX109639, 1:10,000) were obtained from GeneTex; HRP-conjugated anti-rabbit antibody from Santa Cruz (sc-2357, 1:5,000); Alexa Fluor-488 donkey anti-rabbit antibody from Invitrogen (A-21206, 1:250); DAPI from Vector Laboratories; sodium pyruvate, polybrene, puromycin, thymidine, uridine, adenosine, cytidine and inosine from Sigma; aspartic acid from Acros; glutamic acid from Fisher Scientific; blasticidin from Invivogen; antimycin A and piericidin from Enzo Life Sciences; oligomycin from EMD Millipore; phenformin from Fluka; TFB-TBOA and UCPH 101 from Tocris; and Matrigel from Corning. The identities of all the cell lines used in this study were authenticated by single tandem repeat (STR) profiling. All the cell lines were routinely tested for mycoplasma contamination every two months. Among all the cell lines, three of them were in ICLAC as misidentified cell lines but included in our analysis for diversity due to their oncogene status and metabolic phenotypes: RPMI-8402 is an asparagine auxotroph leukaemia cell line, U-937 is a rare histiocytic lymphoma cell line, and HPB-ALL is a cell line with Notch-activating mutations. Identities of these cell lines were authenticated by STR profiling (Supplementary Fig. 1c ). Cell lines were cultured in RPMI medium containing 1 mM glutamine, 10% fetal bovine serum, penicillin and streptomycin. For proliferation assays under aspartate and glutamate depletion and for tracing experiments, RPMI without amino acids (US Biologicals-R8999) was used, supplemented with individual amino acids at RPMI concentrations. For oxygen consumption experiments, assay media consisted of RPMI media with L-glutamine and without sodium bicarbonate (Corning, 50-020-PC). Dialysed serum used in aspartate and glutamate depletion experiments was prepared using Dialysis Tubing (Fisher Scientific) and fetal bovine serum (Sigma). For tracing experiments, [U-13 C]-L-aspartic acid (CIL, CLM-1801-H) and L-aspartic acid-15N (CIL, NLM-718-0.5) were used. [ 14 C(U)]-L-Aspartic acid (Moravek, MC139) was used for aspartate uptake assays.
Generation of the lentiviral sgSLC1A3 was achieved via ligation of hybridized oligos (below) into lentiCRISPR-v1 vector linearized with BsmBI by ligation (NEB). sgSLC1A3_5F, caccgCAAGTACTTCTCCTTTCCTG; sgSLC1A3_5R, aaacCAGGAAAGGAGAAGTACTTGc. Mutagenesis by PCR-overlap extension and Gibson assembly was used for sgRNA-resistant SLC1A3 cDNA generation.
The primers used for the two PCR reactions with the previously generated PMXS-ires-blast-SLC1A3 as a template are below:
S LC 1A 3_F, G CCGGATCTAGCTAGTTAATTAAGCCACCATGACTAAAAGC AATGGAGAAGAGCCC;
SLC1A3-gRes_R, CATCCTCATCAGAAGTTCACCGGGGAAGGAGAAGTACTTGACTTC;
SLC1A3-gRes_F, GAAGTCAAGTACTTCTCCTTCCCCGGTGAACTTCTGATGAGGATG; SLC1A3_R, GGGCGGAATTTACGTAGCCTACATCTTGGTTTCACTGTCGATGGG.
Proliferation assays. Cell lines were cultured in 96-well plates at 1,000 cells per well in a final volume of 0.2 ml RPMI-1640 media (Corning) under the indicated treatments. For adherent cells, drugs were added 2 h after plating. An initial time point of untreated cells was used for normalization. After 5 days of growth, 40 μ l of Cell Titer Glo reagent (Promega) was added and luminescence was read using a SpectraMax M3 plate reader (Molecular Devices). Data is presented as fold change in luminescence relative to the mean final luminescence of untreated cells. For aspartate and glutamate depletion, a custom RPMI media without amino acids (US biologicals) supplemented with 10% dialysed FBS was used by adding all the amino acids except for aspartate, glutamate and asparagine (supplemented with 150 μ M aspartate or glutamate when indicated).
Cell counting assays. Cell lines were plated in 6-well plates at 1,000-5,000 cells per well in standard conditions (normoxia) and in a hypoxia chamber (INVIVO) set to 0.5% O 2 . For hypoxic conditions, culture media were pre-incubated for 24 h. After 5 days of growth, cells were trypsinized and counted using a Beckman Z2 Coulter Counter with a size selection setting of 8-30 μ m.
Aspartate uptake. Adherent cells were plated in 6-well plates at 200,000 cells per well 24 h before the assay. Each well was then washed three times before the uptake experiment with Hank's Balanced Solution (HBSS, Invitrogen). For suspension cell lines, 500,000 cells were pelleted by centrifugation and washed three times with HBSS. Uptake assays were done in 1 ml of HBSS supplemented with 5 mM HEPES and 2 mM glucose and the kinetic measurement at 37 °C was initiated by adding 0.1 μ Ci of L-aspartic acid [ 14 C(U)] per well. An initial reference value was taken for every cell line by washing away the labelled aspartate after addition of 1 ml of cold HBSS buffer supplemented with 150 μ M of unlabelled L-aspartate. After 10 min of assay, the same procedure for stopping the reaction was used both for adherent (three washes per well) or suspension cells (centrifugation of cells in 1.5 ml tube at 850 g and three consecutive washes), before lysis in 400 μ l of lysis buffer (0.1 N NaOH and 0.01% SDS) for 10 min at room temperature. 50 μ l of cell lysate was used for protein quantification and the remaining 350 μ l was mixed in scintillation vials with 5 ml of ScintiSafe Econo Cocktail (Fisher). Radioactivity was measured in a Tri-Carb 2910 Liquid Scintillation Analyzer (Perkin Elmer) and the counts per minute (cpm) for each vial were normalized by microgram of protein and presented as relative to the initial time point.
Generation of knockout and cDNA-overexpression cell lines. sgRNA targeting SLC1A3 (GCAAGTACTTCTCCTTTCCTG) was cloned into lentiCRISPR-v1 linearized with BsmBI by ligation (NEB). Lentiviral vector expressing the sgRNA was transfected into HEK293T cells with lentiviral packaging vectors VSV-G and Delta-VPR using XtremeGene transfection reagent (Roche). For overexpression of aspartate transporters, retroviral vectors with indicated cDNAs were transfected along with retroviral packaging plasmids (Gag-pol and VSV-G) to HEK293T cells. 48 h after transfection, virus particles were collected and filtered using a 0.45 mm filter to eliminate cells. Target cells were plated in 6-well tissue culture plates and infected in media containing the virus and 8 mg ml −1 of polybrene. To increase transduction efficiency, a spin infection was performed by centrifugation at 1,200 g for 1.5 h. 48 h after the infection, selection of transduced cells was performed by addition of puromycin (for sgRNA lentiviral vector) or blasticidin (for overexpression retroviral vectors). SLC1A3-knockout cells were single-cell isolated by serial dilution into a 96-well plate containing 0.1 ml of media. Single-cell clones were grown for three weeks, and the resultant SLC1A3 −/− clones were validated by western blot and expanded.
Metabolite profiling and isotope tracing. For the initial metabolite profiling experiment in resistant and sensitive lines, each indicated cell line (1.5 million cells per replicate) was cultured as triplicates in 6-well plates and treated for 8 h with piericidin (10 nM). For aspartate tracing experiments in A549 and PANC-1 cell lines, 150,000 cells per well were pretreated with 10 nM piericidin or pre-incubated at 0.5% oxygen, as well as in RPMI without piericidin and at 21% oxygen. After 12 h, media was changed and replaced with 2 ml of custom RPMI media lacking aspartate, glutamate and asparagine and supplemented with [U-13 C]-L-aspartate (150 μ M or 20 μ M) or [ 15 N]-L-aspartate (150 μ M or 20 μ M) under indicated treatments for an additional 24 h. Cells were washed three times with 1 ml of cold 0.9% NaCl, and polar metabolites were extracted in 1 ml of cold 80% methanol containing internal standards (MSK-A2-1.2, Cambridge Isotope Laboratories). After extraction, samples were nitrogen-dried and stored at − 80 °C until analysis by liquid chromatography-mass spectrometry (LC-MS). Analysis was conducted on a QExactive benchtop orbitrap mass spectrometer equipped with an Ion Max source and a HESI II probe, which was coupled to a Dionex UltiMate 3000 UPLC system (Thermo Fisher Scientific, San Jose, CA). External mass calibration was performed using the standard calibration mixture every 7 days.
Dried polar samples were resuspended in 100 µ l water, and 2 µ l wasinjected into a ZIC-pHILIC 150 × 2.1 mm (5 µ m particle size) column (EMD Millipore). Chromatographic separation was achieved using the following conditions: buffer A was 20 mM ammonium carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile. The column oven and autosampler tray were held at 25 °C and 4 °C, respectively. The chromatographic gradient was run at a flow rate of 0.150 ml min −1 as follows: 0-20 min: linear gradient from 80% to 20% B; 20-20.5 min: linear gradient from 20% to 80% B; 20.5-28 min: hold at 80% B. The mass spectrometer was operated in full-scan, polarity switching mode with the spray voltage set to 3.0 kV, the heated capillary held at 275 °C, and the HESI probe held at 350 °C. The sheath gas flow was set to 40 units, the auxiliary gas flow was set to 15 units, and the sweep gas flow was set to 1 unit. The MS data acquisition was performed in a range of 70-1,000 m/z, with the resolution set at 70,000, the AGC target at 10 × 10 6 , and the maximum injection time at 20 msec. Relative quantitation of polar metabolites was performed with XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific) using a 5 ppm mass tolerance and referencing an in-house library of chemical standards. For stable isotope tracing studies, fractional labelling was corrected for natural abundance using an in-house algorithm, based on that discussed previously 36 . Metabolite levels were normalized to the total protein amount for each condition.
Oxygen consumption measurements. Oxygen consumption of intact cells was measured using an XF96 Extracellular Flux Analyzer (Seahorse Bioscience). For adherent cell lines (A549, KP lung and KP pancreas), 15,000 cells were plated 12 h before the assay using RPMI 8226 (Corning no. 50-020-PC) assay media as previously described 37 . Basal oxygen consumption measurements were normalized by protein levels.
Determination of NAD + /NADH ratios. For measurement of NAD + /NADH, manufacturer instructions for NAD/NADH Glo Assay were followed (Promega) with addition of previously reported modifications to the protocol 3 . Cells were incubated at 21% and 0.5% O 2 24 hr before being trypsinized and plated at a confluence of 400,000 cells per well in triplicates. After 24 h incubation, cells were lysed in cold DTAB lysis buffer (1% dodecyltrimethylammonium bromide in 0.2 N NaOH diluted 1:1 in PBS). Briefly, to measure NADH, a portion of the extracts were heated to 75 °C for 30 min in a basic lysis buffer. For NAD + measurement, samples were further diluted 1:1 with 0.4 N HCl and heated to 60 °C for 15 min, with the acidic conditions of this incubation degrading NADH. After quenching 1 nature research | reporting summary A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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